Study on Tailored Treatment in Elderly Patients With Newly Diagnosed Primary Lymphoma of Central Nervous System
Status:
Recruiting
Trial end date:
2023-10-31
Target enrollment:
Participant gender:
Summary
Primary central nervous system lymphomas are rare aggressive malignancies, usually treated in
two steps: an induction phase (where a combination of chemotherapy is given) followed by a
consolidation phase (where patients usually receive one of the following: whole-brain
irradiation, chemotherapy supported by autologous stem-cell transplantation, other type of
chemotherapy, or are just observed).
The feasibility of this overall strategy, for several reasons, is limited in elderly patients
.
This study involves patients aged ≥70 years. The more fit patients will receive the standard
chemotherapy combination (high-dose methotrexate, procarbazine and rituximab) as induction.
Responding patients will receive either procarbazine or lenalidomide as maintenance therapy;
the aim is to evaluate the efficacy of these two drugs.
The more fragile patients will receive a less aggressive therapy consisting of concomitant
whole-brain radiotherapy, temozolomide and rituximab as induction therapy, followed by
temozolomide as maintenance treatment; the aim is to evaluate the efficacy of this
combination of treatment.
Phase:
Phase 2
Details
Lead Sponsor:
International Extranodal Lymphoma Study Group (IELSG)